{
    "clinical_study": {
        "@rank": "146124", 
        "acronym": "RUBIS", 
        "arm_group": {
            "arm_group_label": "Rubidium PET", 
            "arm_group_type": "Experimental", 
            "description": "Rubidium PET"
        }, 
        "brief_summary": {
            "textblock": "The  main objective of this study will be to compare the diagnostic performances of\n      82Rubidium-PET associated to pharmacologic stress (Persantine) to 99mTc-Sestamibi-SPECT with\n      CZT cameras associated to a stress test (exercise, pharmacological, mixed) for detection of\n      myocardial ischemia in a population of overweighed patients on one hand, and women on the\n      other hand, in a population with an intermediate prevalence of coronary artery disease (\u2265 3\n      cardiovascular risk factors in asymptomatic patients or prevalence of CAD \u2265 30 % using the\n      DIAMOND-FORRESTER score in symptomatic patients)."
        }, 
        "brief_title": "Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myocardial Ischemia", 
        "condition_browse": {
            "mesh_term": [
                "Myocardial Ischemia", 
                "Coronary Artery Disease", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The  main objective of this study will be to compare the diagnostic performances of\n      82Rubidium-PET associated to pharmacologic stress (Persantine) to 99mTc-Sestamibi-SPECT with\n      CZT cameras associated to a stress test (exercise, pharmacological, mixed) for detection of\n      myocardial ischemia in a population of overweighed patients on one hand, and women on the\n      other hand, in a population with an intermediate prevalence of coronary artery disease (\u2265 3\n      cardiovascular risk factors in asymptomatic patients or prevalence of CAD \u2265 30 % using the\n      DIAMOND-FORRESTER score in symptomatic patients).\n\n      Secondary objectives. (1) Comparison between the size and intensity of myocardial ischemia\n      quantified using the sum difference score, left ventricular function at stress and at rest,\n      measured with 99mTc-Sestamibi-SPECT with CZT cameras and 82Rubidium-PET.\n\n      (2) Comparison between the values of coronary fractional flow reserve measured invasively\n      and noninvasively with 82Rubidium-PET in patients with stenosis \u2265 50 % on coronary\n      angiography.\n\n      (3) Comparison of the effective dose caused by radiation exposure with 99mTc-Sestamibi-SPECT\n      with CZT cameras and 82Rubidium-PET.\n\n      (4) Comparison of the costs of the two diagnostic strategies in this population of patients.\n\n      Inclusion criteria: Overweighed (body mass index \u2265 25) or women addressed in the Department\n      of Nuclear Medicine for diagnostic cardiac scintigraphy with an intermediate pre-test\n      prevalence of CAD (\u2265 3 cardiovascular risk factors in asymptomatic patients or prevalence of\n      CAD \u2265 30 % using the DIAMOND-FORRESTER score in symptomatic patients).\n\n      Non-inclusion criteria: Pregnant women; contraindication to dipyridamole injection.\n\n      Number of patients: 261 patients\n\n      Duration of the study. Duration of the study for a patient will be 12 months. Total duration\n      of the study will be 20 months, including an 8-month inclusion time period.\n\n      Primary endpoint: Patients will be classified as positive in case of:\n\n        -  Myocardial ischemia defined as the presence of coronary stenosis \u2265 50 % on coronary\n           angiography with functional impairment of blood flow confirmed by invasive measurement\n           of coronary flow reserve (fractional flow reserve, FFR < 0.8), or, in absence of\n           measurement of FFR, a critical coronary stenosis confirmed by the validation committee\n           of coronary angiographies.\n\n        -  In absence of coronary angiography, the presence of cardiovascular event\n           (cardiovascular or unknown cause of death, admission for acute coronary syndrome,\n           unstable angina, myocardial ischemia or coronary revascularization) validated by the\n           endpoint adjudication committee in the year following inclusion of the patient in the\n           study.\n\n      Secondary endpoints: (1) Size and intensity of myocardial ischemia quantified using the sum\n      difference score and, left ventricular function at stress and at rest, measured with\n      99mTc-Sestamibi-SPECT with CZT cameras and 82Rubidium-PET. (2) Values of coronary fractional\n      flow reserve measured invasively and noninvasively with 82Rubidium-PET in patients with\n      stenosis \u2265 50 % on coronary angiography. (3) Effective dose caused by radiation exposure\n      with 99mTc-Sestamibi-SPECT with CZT cameras and 82Rubidium-PET. (4) Costs of the two\n      diagnostic strategies in this population of patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA :\n\n        - Overweighed (body mass index \u2265 25) or women addressed in the Department of Nuclear\n        Medicine for diagnostic cardiac scintigraphy with an intermediate pre-test prevalence of\n        CAD (\u2265 3 cardiovascular risk factors in asymptomatic patients or prevalence of CAD \u2265 30 %\n        using the DIAMOND-FORRESTER score in symptomatic patients).\n\n        EXCLUSION CRITERIA :\n\n          -  Pregnant women;\n\n          -  Contraindication to dipyridamole injection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "261", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679886", 
            "org_study_id": "AOM 11066"
        }, 
        "intervention": {
            "arm_group_label": "Rubidium PET", 
            "description": "Rubidium PET", 
            "intervention_name": "Rubidium PET", 
            "intervention_type": "Radiation", 
            "other_name": "Rubidium PET"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Position emission tomography;", 
            "Rubidium;", 
            "Women;", 
            "Overweighted patients"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "contact": {
                "email": "dominique.leguludec@bch.aphp.fr", 
                "last_name": "Dominique LE GULUDEC, MD, PhD", 
                "phone": "01.40.25.84.10", 
                "phone_ext": "+ 33"
            }, 
            "contact_backup": {
                "email": "fabien.hyafil@bch.aphp.fr", 
                "last_name": "Fabien HYAFIL, MD", 
                "phone": "01.40.25.64.75", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "75018"
                }, 
                "name": "Groupe Hospitalier Bichat - Claude Bernard"
            }, 
            "investigator": {
                "last_name": "Dominique LE GULUDEC, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparison of the Diagnostic Performances of 82Rubidium Positron Emission Tomography and Conventional Scintigraphy With CZT Cameras for Detection of Myocardial Ischemia in a Population of Overweighed Patients and Women", 
        "overall_contact": {
            "email": "dominique.leguludec@bch.aphp.fr", 
            "last_name": "Dominique LE GULUDEC, MD, PhD", 
            "phone": "01.40.25.84.10", 
            "phone_ext": "+ 33"
        }, 
        "overall_contact_backup": {
            "email": "fabien.hyafil@bch.aphp.fr", 
            "last_name": "Fabien HYAFIL, MD", 
            "phone": "01,40,25,64,75", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Dominique LE GULUDEC, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be classified as positive in case of:\nCoronary stenosis \u2265 50 % on coronary angiography and fractional flow reserve < 0.8, or, in absence of FFR, a critical coronary stenosis.\nIn absence of coronary angiography, presence of cardiovascular event during the following year.", 
            "measure": "Myocardial ischemia", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679886"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Size and intensity of myocardial ischemia quantified using the sum difference score,\nLeft ventricular function at stress and at rest\nValues of FFR measured invasively and noninvasively\nEffective dose caused by radiation exposure\nCosts of the two diagnostic strategies", 
            "measure": "Size and intensity of myocardial ischemia", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}